ALVAC-HIV (vCP2438)/Bivalent Subtype C gp120/MF59 / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines. (PubMed, Front Immunol) - "We retrospectively analyzed data from HVTN 100, a clinical trial conducted in South Africa during which 143 adults AMAB and 109 AFAB aged 18-40 years without HIV received ALVAC-HIV vCP2438 plus bivalent subtype C gp120/MF59 or placebo at 0, 1, 3, 6, and 12 months. While vaccine recipients AFAB demonstrated higher ADCC responses, AMAB exhibited higher CD4+ T cell response rates. Future analyses should investigate whether vaccine factors such as platform, dosing and adjuvants contribute to sex-based differences in immunogenicity of experimental HIV vaccines."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4 • GZMB • IFNG

Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. (PubMed, Vaccine) - "Vaccine receipt, female sex at birth, older age, and region may affect reactogenicity."

Journal • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Pain

HVTN702: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (clinicaltrials.gov) - P2/3 | N=5404 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Phase classification: P2b ➔ P2/3

Phase classification • Human Immunodeficiency Virus • Infectious Disease